ROGER BELLAMY: Open Payments
NPI 1699968826 · TEMECULA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,616 in 136 payments from 17 companies in 2025. Trend: 2023 $1,920 · 2024 $2,268 · 2025 $2,616
Food & beverage: $2,516Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $393 |
| UCB, Inc. | 15 | $321 |
| Amgen Inc. | 19 | $299 |
| GENZYME CORPORATION | 11 | $239 |
| Galderma Laboratories, L.P. | 17 | $206 |
| Lilly USA, LLC | 12 | $178 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $159 |
| Arcutis Biotherapeutics, Inc. | 11 | $156 |
| Janssen Biotech, Inc. | 6 | $116 |
| REVANCE THERAPEUTICS, INC. | 1 | $106 |
Products named: Bimzelx, Otezla, SKYRIZI, DUPIXENT, NEMLUVIO, TALTZ, Zoryve, TREMFYA.
Industry payments across CA — which companies pay providers there.
